Transaction is anticipated to be completed in third quarter 2025 Planned Cortigent Nasdaq listing intended to drive value for ...

Vivani Medical (Nasdaq:VANI) announced that it filed a Form 10 registration statement with the SEC to spin off its ...

Vivani Medical plans to spin off Cortigent, allowing both companies to focus on their specialized therapeutic areas by Q3 2025. Vivani Medical, Inc. has announced plans to spin off its subsidiary ...

Vivani Medical will spin off Cortigent, its neurostimulation business, as an independently publicly traded company as it looks to prioritise its portfolio of weight loss drug implants. While ...

Cortigent’s Orion ® artificial vision system, which is in development to treat blindness, completed an initial 6-year clinical study in 2024, with encouraging safety and efficacy results ...

ALAMEDA, Calif. - Vivani Medical, Inc. (NASDAQ: VANI), a biopharmaceutical company specializing in long-acting drug implants, announced the filing of a Form 10 registration with the SEC for its ...

Cortigent is developing the Stroke Recovery System to improve the recovery of arm and hand movement in people who have suffered paralysis due to stroke Spin-off will allow Vivani to focus on its ...

Cortigent is developing the Orion ® Visual Cortical Prosthesis System to provide meaningful visual perception to people who are blind Cortigent is developing the Stroke Recovery System to improve ...

Transaction is anticipated to be completed in third quarter 2025 Planned Cortigent Nasdaq listing intended to drive value for Vivani and Cortigent stockholders Cortigent is developing the Orion ...